Cardiovascular rehabilitation increase arterial compliance in type 2 diabetic patients with coronary artery disease.
OBJECTIVE
The effect of a cardiovascular rehabilitation program on arterial compliance in type 2 diabetes mellitus with coronary disease was studied.


METHODS
Hemodynamic data and arterial compliance were measured with a tonometer (HDI/Pulse wave CR-2000) in coronary artery disease patients with (n=32) and without (n=24) type 2 diabetes before and after a 6-week multidisciplinary cardiac rehabilitation program.


RESULTS
A decrease in heart rate and an increase in stroke volume without significant change in resting cardiac output were obtained in diabetic patients. Arterial compliance of both small and large arteries was significantly increased. In 10 diabetic patients, this increase could be related to an increase in the anti-hypertensive treatment and to the decreased blood pressure. In the 22 remainders, the small artery compliance was significantly increased independently of blood pressure change.


CONCLUSIONS
Exercise training as well as optimization of diabetes and dyslipidemia treatment could explain the improvement of arterial compliance. If these changes are long-lasting and if they improve prognosis remains to be evaluated.
Mourot
L
L
EA 3920 and IFR133, Université de Franche Comté, Physiologie, Faculté de Médecine, Besançon, France. mourotlaurent@hotmail.com
Boussuges
A
A
Campo
P
P
Maunier
S
S
Debussche
X
X
Blanc
P
P
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001160:Arterioles / Q000187:drug effects / Q000503:physiopathology; D015992:Body Mass Index; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology / Q000534:rehabilitation*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000503:physiopathology / Q000534:rehabilitation*; D004232:Diuretics / Q000627:therapeutic use; D015444:Exercise; D006339:Heart Rate / Q000502:physiology*; D006439:Hemodynamics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008365:Manometry; D010349:Patient Compliance; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011674:Pulse; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents